News Interim report for 1H 2023 Please read the full announcement in PDF Attachment 2023_54_Q22023_CompanyAnnouncement Continue Reading Previous Novartis remibrutinib Phase III trials met their primary endpoints and showed rapid symptom control in chronic spontaneous urticariaNext Novozymes delivers results within expectations in the first half of 2023 and narrows the full year outlook Related Stories AI News Aptiv Delivering Production-Ready Edge AI with Long-Term Support with NVIDIA News OpenEnvoy Launches Ask OE to Solve Enterprise Finance AI’s Foundational Problem News Pax8 to Launch Relationship with inforcer, Expanding Microsoft 365 Security, Governance and Copilot Readiness for MSPs News Pax8 Expands the Marketplace Platform to Help Partners Run and Scale Their Business News DTEX Introduces AI Risk Management to Secure the Agentic Enterprise News Fortinet launches Singapore NDR cloud PoP to strengthen threat detection across ASEAN